Since 2013, the FDA has approved 9 antibiotics from small companies. Today, all but one company behind those antibiotics have either gone bankrupt, were acquired for pennies on the dollar, or are under water. After surviving the long, costly road of R&D and securing FDA approval for their treatment, many antimicrobial makers face the “second valley of death” — a broken market that threatens their survival.